Natco Pharma receives 9 observations from USFDA

The United States Food and Drug Administration (USFDA) has completed a regulatory inspection of Natco Pharma’s facility in Kothur Village, Hyderabad. 

The USFDA has issued 9 observations to the formulation plan with no repeat observations. The inspection was conducted during the period May 30, 2019 to June 05, 2019. The company has stated the nature of the observation as mostly procedural and non-related to data integrity and that all of the observations can be addressed within a short period of time. 

Natco Pharma is engaged in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and international markets. 

On Thursday, the shares of Natco Pharma opened at Rs. 547 against Tuesday’s close of Rs. 542. At around 12:22 hours, the stock was trading at Rs. 545.20, higher by 0.50 per cent. The share movement was quite volatile as post the news it dropped 2 per cent but recovered soon. It reached an intraday high of Rs. 555 and an intraday low of Rs. 535 per share on the BSE. The 52-week high stood at Rs. 848.30 and 52-week low was at Rs. 480 per share on the BSE.